Inovio Pharmaceuticals In... (INO)
1.84
-0.14 (-7.07%)
At close: Mar 03, 2025, 3:59 PM
1.84
-0.25%
After-hours: Mar 03, 2025, 04:04 PM EST
No 1D chart data available
| Bid | 1.84 |
| Market Cap | 66.6M |
| Revenue (ttm) | 260.95K |
| Net Income (ttm) | -32.4B |
| EPS (ttm) | -4.43 |
| PE Ratio (ttm) | -0.42 |
| Forward PE | -0.71 |
| Analyst | Buy |
| Ask | 1.91 |
| Volume | 535,934 |
| Avg. Volume (20D) | 1,125,250 |
| Open | 1.98 |
| Previous Close | 1.98 |
| Day's Range | 1.83 - 2.00 |
| 52-Week Range | 1.74 - 14.75 |
| Beta | 0.89 |
About INO
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery o...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 8, 1998
Employees 127
Stock Exchange NASDAQ
Ticker Symbol INO
Website https://www.inovio.com
Analyst Forecast
According to 5 analyst ratings, the average rating for INO stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 713.01% from the latest price.
Buy 60.00%
Hold 40.00%
Sell 0.00%
Next Earnings Release
Inovio Pharmaceuticals Inc. is scheduled to release its earnings on Mar 14, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+18.13%
Shares of vaccine makers are trading higher after ...
Unlock content with
Pro Subscription
2 months ago
-38.3%
Inovio Pharmaceuticals shares are trading lower after the company announced a public offering of 10 million shares for gross proceeds of $30 million.
